Raymond James Financial Inc. Takes Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Raymond James Financial Inc. acquired a new stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 79,044 shares of the biotechnology company's stock, valued at approximately $707,000. Raymond James Financial Inc. owned 0.14% of Astria Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. boosted its holdings in Astria Therapeutics by 152.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 314,265 shares of the biotechnology company's stock worth $3,460,000 after acquiring an additional 189,727 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Astria Therapeutics in the 3rd quarter worth $613,000. Barclays PLC increased its position in shares of Astria Therapeutics by 70.5% during the third quarter. Barclays PLC now owns 92,651 shares of the biotechnology company's stock worth $1,020,000 after acquiring an additional 38,321 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Astria Therapeutics by 101.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 39,144 shares of the biotechnology company's stock valued at $431,000 after acquiring an additional 19,735 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Astria Therapeutics during the 4th quarter valued at about $107,000. Institutional investors own 98.98% of the company's stock.

Remove Ads

Astria Therapeutics Stock Performance

Shares of ATXS traded down $0.02 during mid-day trading on Thursday, reaching $4.06. The company had a trading volume of 534,043 shares, compared to its average volume of 389,782. The company has a market capitalization of $229.12 million, a price-to-earnings ratio of -1.94 and a beta of 0.68. The firm has a 50-day moving average price of $6.16 and a 200 day moving average price of $8.61. Astria Therapeutics, Inc. has a 52 week low of $3.56 and a 52 week high of $12.92.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.01. As a group, research analysts forecast that Astria Therapeutics, Inc. will post -1.65 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ATXS. HC Wainwright restated a "buy" rating and issued a $16.00 target price on shares of Astria Therapeutics in a report on Tuesday, March 11th. Wedbush restated an "outperform" rating and set a $28.00 price target (up from $27.00) on shares of Astria Therapeutics in a research note on Wednesday, March 12th. JMP Securities assumed coverage on Astria Therapeutics in a report on Friday, January 31st. They set an "outperform" rating and a $26.00 target price for the company. Finally, Citizens Jmp raised Astria Therapeutics to a "strong-buy" rating in a report on Friday, January 31st. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $26.60.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.